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Methods: Forty patients with known symptomatic secondary pulmonary hypertension due to val-
vular heart disease, chronic thromboembolic disease, chronic obstructive pulmonary disease, inter-
stitial pulmonary ﬁbrosis, and idiopathic dilated cardiomyopathy were included in this phase II
study. Patients were allocated in a randomized, placebo controlled design to either sildenaﬁl or pla-
cebo for 6 weeks. Baseline and 6 week follow up included assessment of hemodynamic parameters,
functional class using the NYHA classiﬁcation, echocardiographic measurements of pulmonary
artery systolic pressure and left ventricular ejection fraction.
Results: The mean NYHA class at 6 weeks was 2.05 ± 0.4 in the sildenaﬁl group versus 2.6 ± 0.6
in the placebo group, p= 0.02. The mean systolic pulmonary artery pressure signiﬁcantly decreased
in the sildenaﬁl group at 6 weeks (43 ± 4 mmHg), compared to placebo patients (53 ± 7 mmHg),
p= 0.02. Ejection fraction was higher in the sildenaﬁl group, 59 ± 12% versus 54 ± 14% in the
placebo group, but did not reach statistically signiﬁcant difference. Sildenaﬁl was well tolerated with
minimal side effects.
Conclusion: Our data suggest that sildenaﬁl therapy may provide beneﬁts to selected patients with
pulmonary hypertension secondary to cardiac or pulmonary diseases.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Pulmonary arterial hypertension is deﬁned as a group of dis-
eases characterized by a progressive increase in pulmonary vas-
cular resistance, leading to right ventricular failure and
premature death.1 Pathophysiology occurring in patients with
parenchymal lung and or cardiac diseases leading to pulmon-
ary hypertension is not fully understood. Potential mecha-
nisms include vasoconstriction either as a consequence of
hypoxia in the pulmonary circulation or endothelial dysfunc-
tion, smooth muscle proliferation, and vascular remodeling.2
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mance by favorably modulating pulmonary vascular resistance
are receiving increased attention in the management of patients
with parenchymal lung and valvular heart disease who have
co-existent pulmonary hypertension.3 One such treatment is
Sildenaﬁl, a selective phosphodiesterase-5 (PDE 5) inhibitor.
Phosphodiesterases inactivate cyclic guanosine mono phos-
phate (CGMP), the second messenger of prostacycline and ni-
tric oxide. The majority of PDE 5 pathway resides in the lungs
and the urological tract. Sildenaﬁl potentiates the effects of
pulmonary CGMP and enhances the vasodilatory effect of this
pathway. Such an effect can be observed within 15 min of sil-
denaﬁl administration and can produce early beneﬁcial effects
at 6 weeks, moreover can persist for 6 months.4 In addition,
sildenaﬁl has an early positive impact on left ventricular per-
formance.4 This phase II study was designed to assess the short
term effects of sildenaﬁl citrate therapy in patients with sec-
ondary pulmonary arterial hypertension.
2. Patients and methods
2.1. Study design
Forty patients with symptomatic secondary pulmonary arterial
hypertension were allocated in this phase II, prospective, ran-
domized, placebo controlled study. Patients were randomized
using simple randomization (1:1) to either sildenaﬁl therapy in
a titrating dose or placebo. We aimed to assess the safety and
efﬁcacy of oral sildenaﬁl therapy in this category of patients over
a short term (6 weeks). All patients signed an informed consent.
Key inclusion criteria were: patients with symptomatic second-
ary pulmonary hypertension with New York Heart Association
(NYHA) functional classP2, the underlying etiologies of pul-
monary hypertension were: dilated cardiomyopathy, chronic
obstructive pulmonary disease (COPD), chronic thromboem-
bolic disease, interstitial lung disease, and valvular heart disease
(mitral and aortic regurgitation). Key exclusion criteria were:
primary pulmonary hypertension, hypotension, allergy to silde-
naﬁl, ischemic heart disease.
2.2. Baseline and 6 week evaluation
All patients had full history taking, complete general (heart
rate and systemic blood pressure) and local examinations of
the heart, chest and abdomen, twelve lead resting ECG, rou-
tine laboratory investigations, chest X-ray.
 The functional status at baseline and follow up was assessed
using the New York Heart Association (NYHA) class
scale.5
 Transthoracic echocardiography:
Echocardiographic examinationwas performed in each patient
while lying in the left lateral position, using commercially available
ultrasound systems (GH Vingmed ViVid 3 pro N, Norway).
2.2.1. Assessment of the left ventricular function
Left ventricular systolic function was assessed using two-
dimensionally guided M-mode echocardiography in left para-
sternal long axis view by positioning the ultrasound beam justbeyond the mitral leaﬂet tips and as perpendicular as possible
to the ventricular long axis. Left ventricular internal dimen-
sions were measured from the leading edge to the leading edge.
Left ventricular volumes, and ejection fraction (LVEF) were
measured.
2.2.2. Doppler echocardiography
Trans-tricuspid ﬂow velocities were recorded using the contin-
uous-wave Doppler technique from the apical four-chamber
view with the sample volume placed at the tip of the tricuspid
valve and the peak velocity of tricuspid regurgitation(TR) was
assessed and pressure gradient through the tricuspid valve was
calculated according to modiﬁed Bernoli equation; Dp= 4V2
TR. Right atrial pressure (PRA) was estimated during quiet
respiration and forced inspiration in sub-costal view by observ-
ing the degree of dilatation and the respiratory variability in
the inferior vena cava caliber. Pulmonary artery systolic pres-
sure (PASP) was estimated as mentioned before.6
2.3. Study medications
Oral sildenaﬁl/matched placebo was given in a titrated dose,
starting with 25 mg three times daily for 1 week, then the dose
was doubled to 50 mg three times daily according to side ef-
fects and tolerability until 6 week period. Patients were blinded
to their randomization.
3. Statistical analysis
SPSS program was used for analysis of data in the form of
description of quantitative variables in the form of
mean ± SD, and as n (%) for qualitative variables. Paired
sample t-test, and two independent sample Student’s t test
were used for within and between groups analysis of continu-
ous data, respectively. Chi-square test was used for analysis of
categorical data. The probability of type I error (P value) less
than 0.05 was considered signiﬁcant.
4. Results
4.1. Study population
The mean age of the study patients was 56 ± 9 years (range
37–70), 57 ± 8 years in the sildenaﬁl group versus
55 ± 7 years in the placebo group (p= 0.8), 18 patients were
males (45%), and 22 patients were females (55%). The etiolo-
gies of pulmonary hypertension were rheumatic valvular heart
disease (20%), chronic thromboembolism (20%), chronic
obstructive pulmonary (COPD, 20%), interstitial pulmonary
ﬁbrosis (IPF, 20%), and non ischemic dilated cardiomyopathy
(NIDCM, 20%) Table 1.
4.2. Vital sign parameters
The mean heart rate at baseline was 83 ± 8 bpm in all pa-
tients, 84 ± 8 bpm versus 82 ± 8 bpm in sildenaﬁl and pla-
cebo groups, respectively (p= 0.9). At 6 weeks, the mean
heart rate was 84 ± 9 bpm in all patients, 86 ± 9 bpm versus
83 ± 9 bpm in sildenaﬁl and placebo groups, respectively
Table 1 Baseline characteristics of study population.
Variable All patients N= 40 Sildenaﬁl N= 20 Placebo N= 20 P value
Age, years, mean SD 56 ± 9 57 ± 8 55 ± 7 0.8
Sex, males, n (%) 18 (45%) 9 (45%) 9 (45%) 1
Etiology of pulmonary hypertension
1. Rheumatic valvular heart disease 8 (20%) 4 (20%) 4 (20%)
2. Chronic thromboembolism 8 (20%) 4 (20%) 4 (20%)
3. Chronic obstructive pulmonary disease 8 (20%) 4 (20%) 4 (20%)
4. Interstitial pulmonary ﬁbrosis 8 (20%) 4 (20%) 4 (20%)
5. Non ischemic dilated cardiomyopathy 8 (20%) 4 (20%) 4 (20%)
Figure 1 Functional class at baseline and 6 weeks.
Sildenaﬁl in secondary pulmonary hypertension 51(p= 0.7, for within and between groups comparison). The
mean systolic blood pressure at baseline was 119 ± 8 mmHg
in all patients, 121 ± 8 mmHg in the sildenaﬁl group versus
117 ± 8 mmHg in the placebo group (p= 0.8). At 6 weeks,
the mean systolic blood pressure was 119 ± 7 mmHg in all pa-
tients, 115 ± 7 mmHg versus 117 ± 8 mmHg in sildenaﬁl and
placebo groups, respectively (p= 0.6, for within and between
groups comparison). The mean total diastolic blood pressure
at baseline was 74 ± 7 mmHg, 76 ± 6 mmHg versus
73 ± 7 mmHg in sildenaﬁl and placebo groups, respectively
(p= 0.5). The mean diastolic blood pressure after 6 weeks
was 71 ± 5 mmHg, the mean diastolic blood pressure in the
sildenaﬁl group was 71 ± 6 mmHg versus 72 ± 5 mmHg in
the placebo group (p= 0.8, for within and between groups
comparison).
4.3. Functional class
Baseline NYHA class was 2.85 ± 0.36 in all patients,
2.86 ± 0.36 and 2.84 ± 0.36 in sildenaﬁl and placebo patients,
respectively (p= 0.9). The mean NYHA after 6 weeks in the
sildenaﬁl group was 2.05 ± 0.5 versus 2.6 ± 0.6 in the placebo
group (p= 0.02, for both within and between groups compar-
ison). At baseline, 85% of patients who were assigned to silde-
naﬁl therapy had NYHA class III, and 15% had NYHA class
II, after 6 weeks, 15% were in class III, 75% in class II, and
10% in class I. 75% of patients had P1 class improvement
from baseline. In the placebo group, 85% of patients had class
III at baseline, 15% had class II. 6 weeks later, 65%, 30%, andTable 2 Functional class at baseline and 6 weeks.
Variable Sildenaﬁl
N= 20
Mean NYHA class at baseline 2.86a ± 0.36
Mean NYHA class after 6 weeks 2.05a ± 0.5
NYHA class at baseline
Class III, n (%). 17 (85%)b
Class II 3 (15%)
NYHA class after 6 weeks
Class III 3 (15%)b
Class II 15 (75%)
Class I 2 (10%)
One or more class improvement, % 75%
a In the sildenaﬁl group a signiﬁcant decrease in mean NYHA class fro
b In the sildenaﬁl group a signiﬁcant decrease in number NYHA class5% were in Class III, II, I, respectively. 20% of patients had
P1 class improvement from baseline, p= 0.01 (Table 2 and
Fig. 1).
4.4. Echocardiographic data
The mean pulmonary artery systolic pressure (PASP) signiﬁ-
cantly decreased in the sildenaﬁl group from baseline
59 ± 7 mmHg to 43 ± 4 mmHg after 6 weeks (p 0.001). The
PASP did not change in the placebo group from baseline
54 ± 7 mmHg to 53 ± 7 mmHg after 6 weeks (p= 0.7). Be-
tween groups analysis showed a signiﬁcant decrease in pul-
monary artery systolic pressure in sildenaﬁl patients after
6 weeks compared to placebo patients (p= 0.001). LVEF in-
creased in the sildenaﬁl group from baseline 53%± 13 toPlacebo P value
N= 20
2.84 ± 0.36 0.9
2.6 ± 0.6 0.02
17 (85%)
3 (15%)
13 (65%) 0.01
6 (30%) 0.02
1 (5%) 0.03
20% 0.01
m baseline (p value 0.02).
3 from 17 at baseline to 3 after 6 weeks (p value <0.01).
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icant difference (p= 0.4). In placebo patients, LVEF did not
change from baseline 54%± 7 to 54%± 14 after 6 weeks
(p= 0.9). LVEF was higher in the sildenaﬁl group compared
to the placebo group, but did not reach statistical signiﬁcance
(p= 0.5) (Table 3).
4.5. Side effects and tolerability of sildenaﬁl
Two patients developed transient headache but these symp-
toms resolved spontaneously, three patients experienced nau-
sea, resolved after one week of treatment spontaneously
without the need to decrease the dose of sildenaﬁl. No severe
adverse events were reported.
4.6. Subgroup analysis
4.6.1. Rheumatic valvular heart disease
Sildenaﬁl signiﬁcantly reduced PASP from baseline
(63 ± 8 mmHg) to (42 ± 5 mmHg) at 6 weeks (p= 0.001).
In the placebo group, no signiﬁcant changes were detected
(59 ± 10 mmHg, 57 ± 10 mmHg, at baseline and 6 weeks,
respectively). 75% of patients in the sildenaﬁl group versus
25% of patients in the placebo group improvedP1 functional
class compared to baseline (p= 0.01).
4.6.2. Chronic thromboembolic pulmonary disease
There was a signiﬁcant decrease in PASP in the sildenaﬁl
group from baseline 59 ± 3 mmHg to 43 ± 3 mmHg after
6 weeks, p= 0.001, but no changes in placebo patients were
reported, 54 ± 3 mmHg and 54 ± 4 mmHg, respectively.
75% of patients in the sildenaﬁl group versus 25% of patients
in the placebo group improvedP1 functional class (p= 0.01).
4.6.3. IPF
Patients randomized to sildenaﬁl had a signiﬁcant decrease in
PASP from baseline 66 ± 8 mmHg to 46 ± 5 mmHg after
6 weeks (p= 0.001), versus those in the placebo group,
59 ± 4 mmHg and 58 ± 5 mmHg, respectively. Signiﬁcant
improvement in NYHA class was detected in the sildenaﬁl
group; 75% of patients in the sildenaﬁl group versus 25% of
patients in the placebo group improved P1functional class
compared to baseline (p= 0.01).
4.6.4. COPD
Sildenaﬁl signiﬁcantly decreased PASP from baseline
57 ± 6 mmHg to 41 ± 4 mmHg after 6 weeks (p= 0.01), ver-Table 3 Echocardiographic changes from baseline to 6 weeks.
Variable All patients
N= 40
PASP, mean SD,baseline 56 ± 7
PASP, 6 weeks 48 ± 7
LVEF, baseline 54%± 13
LVEF, 6 weeks 56%± 13
PASP = pulmonary artery systolic pressure.
LVEF= left ventricular ejection fraction.
a Within group comparison from baseline to 6 weeks showed a signiﬁcsus the placebo group from baseline 58 ± 6 mmHg to
54 ± 3 mmHg after 6 weeks. 70% of patients in the sildenaﬁl
group versus 20% of patients in the placebo group improved
P1 functional class compared to baseline (p= 0.01).
4.6.5. Non IDCM
Between groups analysis showed a signiﬁcant decrease in
PASP in the sildenaﬁl group from baseline 54 ± 4 mmHg to
44 ± 2 mmHg after 6 weeks (p= 0.01) versus the placebo
group from baseline 51 ± 3 mmHg to 49 ± 2 mmHg after
6 weeks. 100% of patients in the sildenaﬁl group versus 25%
of patients in the placebo group improvedP1 functional class
compared to baseline (p= 0.001).
5. Discussion
In this randomized, placebo controlled study, the efﬁcacy of
sildenaﬁl as a therapeutic option in patients with secondary
pulmonary hypertension was evaluated. Sildenaﬁl signiﬁcantly
reduced pulmonary artery systolic pressure (PASP), improved
left ventricular ejection fraction (LVEF), and induced a signif-
icant improvement in NYHA functional class after 6 weeks of
treatment. The drug had a few side effects and was tolerated
through the entire study period.
In the present study, there were no signiﬁcant changes in
heart rate, systolic blood pressure, or diastolic blood pressure
during the study period. Our ﬁndings were in accordance with
Corbin and colleagues, 20037 who demonstrated that sildenaﬁl
citrate causes only a mild and transient decrease in blood pres-
sure (8–10 mmHg for systolic blood pressure and 5–6 mmHg
for diastolic blood pressure). In a study of patients with severe
coronary artery disease, Herrmann and colleagues, 20008, con-
ﬁrmed that the hemodynamic effects of sildenaﬁl citrate (when
taken alone) are not associated with clinically signiﬁcant hypo-
tension. Gregory et al.,9 showed that sildenaﬁl did not signiﬁ-
cantly change resting heart rate and mean arterial pressure. In
contrast, Guimaraes et al.,10 reported that sildenaﬁl signiﬁ-
cantly reduced blood pressure in the basal position and during
exercise. It also promoted a signiﬁcant reduction in SBP and
DBP during 24 h, daytime and night time.
In this study, sildenaﬁl signiﬁcantly reduced PASP from
baseline 59 ± 7 mmHg to 43 ± 4 mmHg after 6 weeks, and in-
duced a trend toward an increase in ejection fraction from
baseline 53% to 59% after 6 weeks. These ﬁndings were in
accordance with Naveen et al.,11 who showed that pulmonary
arterial pressures were signiﬁcantly decreased after sildenaﬁl
from 107.7 ± 18 mmHg to 90.3 ± 19 mmHg. Ghada et al.,12
reported a signiﬁcant reduction in systolic PAP, mean PAP,Sildenaﬁl Placebo P value
N= 20 N= 20
59 ± 7a 54 ± 7 0.6
43 ± 4a 53 ± 7 0.001
53%± 13 54%± 13 0.8
59%± 12 54%± 14 0.5
ant decrease in PASP in the sildenaﬁl group P= 0.001.
Sildenaﬁl in secondary pulmonary hypertension 53PVR, and PVRI (index) and a trend toward an increase in car-
diac output (CO) after 3 months of oral sildenaﬁl therapy,
compared to baseline. In addition, sildenaﬁl induced a marked
improvement in RV systolic and diastolic function. The in-
crease in RV dP/dtmax/IP in patients who received sildenaﬁl
at 2–4 weeks was sustained through 12–15 weeks. Two mecha-
nisms could account for augmentation of cardiac output with
sildenaﬁl therapy. It is possible that LV afterload reduction
contributed to the improvement in cardiac output with exercise
because a trend toward a decrease in SVR in patients treated
with sildenaﬁl was observed. Alternatively, it is conceivable
that sildenaﬁl increased ventricular contractility. Nagendran
et al.,13 have suggested that PDE5 inhibition can increase
RV contractility in the setting of RV hypertrophy. However,
previous studies in animal models and in humans with heart
failure have indicated that PDE5 inhibition does not alter
myocardial contractility.
We reported that, sildenaﬁl signiﬁcantly improved func-
tional status compared to baseline and placebo group. 75%
of patients had P1 class improvement with sildenaﬁl, mean
NYHA class decreased from a mean 2.85 at baseline to 2.05
at 6 weeks. Our ﬁndings were in accordance with Naveen
et al.,11 who reported an improvement by P1 NYHA func-
tional classes in all patients using sildenaﬁl. Overall NYHA
class, decreased from 2.54 at baseline to 1.31 at follow-up. Pa-
tients showed a remarkable improvement on the six minute
walk test from a baseline of 247.4 ± 75 m to 366.3 ± 94 m
at follow-up. Gregory et al.,9 reported that NYHA class im-
proved in 53% of patients receiving sildenaﬁl compared with
7% in patients receiving placebo and worsened in 13% of pa-
tients receiving sildenaﬁl versus 27% of patients receiving
placebo.
6. Conclusion
Our data suggest that sildenaﬁl therapy may provide a beneﬁt
in selected patients with pulmonary hypertension secondary to
cardiac and pulmonary diseases. The treatment is well toler-
ated, seems to have a beneﬁcial effect on cardiopulmonary
hemodynamic and functional status.
7. Study limitations
1. Small sample size.
2. Short follow up period.
3. Non invasive assessment of PASP.References
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